Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.

Rohrberg KS, Olesen RK, Pfeiffer P, Ladekarl M, Pappot H, Christensen IJ, Høyer-Hansen G, Sørensen M, Skov BG, Buysschaert I, Carmeliet P, Lassen U.

Acta Oncol. 2012 Feb;51(2):234-42. doi: 10.3109/0284186X.2011.619568. Epub 2011 Oct 21.

PMID:
22017239
2.

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.

Rohrberg KS, Pappot H, Lassen U, Westman M, Olesen RK, Pfeiffer P, Ladekarl M, Sørensen M, Christensen IJ, Skov BG.

Cancer Biol Ther. 2011 Apr 15;11(8):732-9. Epub 2011 Apr 15.

PMID:
21330783
3.

Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.

Rohrberg KS, Skov BG, Lassen U, Christensen IJ, Høyer-Hansen G, Buysschaert I, Pappot H.

Cancer Biomark. 2010;7(3):141-51. doi: 10.3233/CBM-2010-0157.

PMID:
21263190

Supplemental Content

Loading ...
Support Center